GlycoMimetics (GLYC) Stock Price, News & Analysis

Company Overview

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.16 to $27.47
• 52-Week Range: N/A
• Volume: 1.05 million shs
• Average Volume: 67,672 shs
• Market Capitalization: $10.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

GLYC Stock Analysis - Frequently Asked Questions

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) posted its earnings results on Wednesday, May, 14th. The biotechnology company reported ($4.00) earnings per share for the quarter, topping the consensus estimate of ($5.00) by $1.00.

When did GlycoMimetics' stock split?

GlycoMimetics's stock reverse split on the morning of Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of GlycoMimetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLYC
• CIK: 1253689
• Web: www.glycomimetics.com
• Phone: (240) 243-1201
• Fax: 301-738-2137
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.88 million
• Net Margins: N/A
• Pretax Margin: -397,340.00%
• Return on Equity: -230.74%
• Return on Assets: -177.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.92
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 64,532,000
• Free Float: 58,901,000
• Market Cap: $10.00 million
• Optionable: Optionable
• Beta: 1.62